# of Displayed Technologies: 3 / 3

Applied Category Filter (Click To Remove): Genetic Engineering


Categories

An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-targeting activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases such as Duchenne muscular dystrophy (DMD) lacking effective therapeutic treatments. DMD is caused by genetic mutations in the DMD gene, which encodes the dystrophin protein. The mutations including missense point mutations, nonsense point mutations, deleti…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
  • Licensing Officer: Davis, Stewart

Compact Cas9-based transcriptional regulators for in vivo gene regulation
TS-045681 — Cas9-derived constructs can be used to modulate gene expression, but physical limitations restrict the application of this technique. Researchers at The Ohio State University have overcome this obstacle by engineering new Cas9-derived transcription factors.
CRISPR/Cas9 systems have revolutionized the field of programmable DNA technology. Recently, a version of the Cas9 protein with a deactivated nuclease domain called “dCas9” was developed. Without this domain, dCas9’s range of activity is limited to recognizing and binding sequence…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
  • Licensing Officer: Ezzell, Janel

Gene delivery to adipose tissue using novel recombinant adeno-associated viral vectors
TS-037310 — An engineered recombinant adeno-associated virus capable of targeting fat tissue previously inaccessible to this viral vector for the purposes of genetic manipulation.
Recombinant adeno-associated viruses (rAAVs) are effective tools for delivering gene therapy treatment and for manipulation of acquired diseases. However, there is no effective method to target adipose tissue and transduction efficiency is low in naturally occurring AAV serotypes. In addition, cur…
  • College: College of Medicine (COM)
  • Inventors: Cao, Lei; Huang, Wei
  • Licensing Officer: Ezzell, Janel

Loading icon